newsfilter
← Earnings
Earnings Releases·

Organogenesis Holdings Inc. — Third Quarter 2026 Earnings Summary

  • Q3 2026 net revenue fell 70% year-over-year to $45.5 million, driven by a 73% decline in Advanced Wound Care, resulting in a net loss of $29.6 million compared to net income of $21.6 million in Q3 2025.
  • Full-year 2026 total net revenue guidance was lowered to $179.4–$200.0 million, reflecting a 65–68% decline from 2025, with the second-half revenue decline revised to 68–74% year-over-year.
  • Cash reserves decreased to $26.9 million as of September 30, 2026, from $94.3 million at year-end 2025, while the accumulated deficit widened significantly to $(182.4) million.
  • Management attributes the market reset and revenue contraction primarily to CMS 2026 Medicare reimbursement changes, though they anticipate sequential revenue improvement in Q4 2026.
  • The company recorded $8.9 million in restructuring charges, $3.3 million in inventory write-downs, and $5.6 million in R&D program termination costs during the nine months ended September 30, 2026.
Company
ORGANOGENESIS HOLDINGS INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic